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Abstract We investigated the in vivo metabolic fate of pre-
b HDL particles in human apolipoprotein A-I transgenic
(hA-I Tg) mice. Pre-b HDL tracers were assembled by incuba-
tion of [125I]tyramine cellobiose-labeled apolipoprotein A-I
(apoA-I) with HEK293 cells expressing ABCA1. Radiola-
beled pre-b HDLs of increasing size (pre-b1, -2, -3, and -4
HDLs) were isolated by fast-protein liquid chromatography
and injected into hA-I Tg-recipient mice, after which plasma
decay, in vivo remodeling, and tissue uptake were moni-
tored. Pre-b2, -3, and -4 had similar plasma die-away rates,
whereas pre-b1 HDL was removed 7-fold more rapidly. Ra-
diolabel recovered in liver and kidney 24 h after tracer injec-
tion suggested increased (P , 0.001) liver and decreased
kidney catabolism as pre-b HDL size increased. In plasma,
pre-b1 and -2 were rapidly (,5 min) remodeled into larger
HDLs, whereas pre-b3 and -4 were remodeled into smaller
HDLs. Pre-b HDLs were similarly remodeled in vitro with
control or LCAT-immunodepleted plasma, but not when
incubated with phospholipid transfer protein knockout
plasma. Our results suggest that initial interaction of
apoA-I with ABCA1 imparts a unique conformation that par-
tially determines the in vivo metabolic fate of apoA-I, result-
ing in increased liver and decreased kidney catabolism as
pre-b HDL particle size increases.—Mulya, A., J-Y. Lee,
A. K. Gebre, E. Y. Boudyguina, S-K. Chung, T. L. Smith,
P. L. Colvin, X-C. Jiang, and J. S. Parks. Initial interaction
of apoA-I with ABCA1 impacts in vivo metabolic fate of
nascent HDL. J. Lipid Res. 2008. 49: 2390–2401.
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protein • lecithin:cholesterol acyltransferase • in vivo catabolism • high
density lipoproteins • ABCA1 transporter
HDLs are the smallest lipoprotein (7–12 nm in diam-
eter) and the most dense (1.063–1.21 g/ml) of the plasma
lipoprotein particles and consist of a surface monolayer
of protein, phospholipid (PL), and free cholesterol sur-
rounding a hydrophobic core of triglyceride (TG) and
cholesteryl ester (CE) (1). Apolipoprotein A-I (apoA-I) is
the predominant apolipoprotein on HDLs, representing
80–90% of the total protein (2). Interest in understanding
HDL metabolism stems from the well-documented fact
that plasma HDL cholesterol concentrations are inversely
associated with coronary heart disease risk (3). This in-
verse association is most likely due to the role of HDLs
in reverse cholesterol transport (RCT), a process in which
HDLs transport excess cholesterol from peripheral tissue
to the liver for secretion into bile and, ultimately, for excre-
tion in the feces (4). However, other functions of HDL
may result in protection against development of coronary
heart disease, including protecting plasma LDLs from oxi-
dation (5), decreasing inflammation (6), and improving
vascular function (7).
HDLs are a heterogeneous mixture of discrete-sized par-
ticles that can be separated by density (8), size (9), electro-
phoretic mobility (10), and apolipoprotein content (11).
Analysis of plasma HDL particles by agarose gel electro-
phoresis has shown that most plasma HDLs migrate in
the a position (90–95% of total HDL in normal human
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plasma), whereas only 5–10% migrate in the pre-b posi-
tion (designated as pre-b HDL) (12). The term pre-b
HDL has evolved to describe any lipoprotein that migrates
in the pre-b position on agarose gel electrophoresis, in-
cluding lipid-free apoA-I, lipid-poor HDL (containing only
a few molecules of lipid), and discoidal HDLs (containing
PL, cholesterol, and apoA-I, but no core lipid) (13, 14).
Lipid-poor and discoidal HDLs are referred to as nascent
HDLs because they must undergo maturation processes
that ultimately result in their conversion into mature,
spherical plasma HDLs containing a core of hydrophobic
lipid (i.e., CE and TG). Although pre-b HDLs are minor
constituents of plasma HDL, there is an intense interest in
how these particles are formed and catabolized, inasmuch
as several studies have suggested that pre-b HDLs are the
initial acceptors of peripheral tissue cholesterol in RCT
(15, 16). Despite the potential importance of pre-b HDLs
in RCT, little is known about their in vivo metabolism.
We previously isolated a pre-b HDL fraction from plasma
of human apoA-I transgenic (hA-I Tg) mice using a com-
bination of anti-human apoA-I immunoaffinity and size-
exclusion chromatography and investigated its in vivo
metabolism in hA-I Tg mice (17), whose plasma HDL size
heterogeneity resembles that in human plasma (18, 19).
The pre-b HDL tracer isolated from hA-I Tg mouse or
human plasma, which was ,7.1 nm in diameter, exhib-
ited two metabolic fates in vivo. About 60% of the pre-
b HDL tracer was rapidly removed from plasma and
catabolized by the kidney, whereas the remainder was
rapidly transferred to medium-sized (8.6 nm-diameter)
plasma HDL particles, resulting in a slower removal rate
from plasma and a preferential uptake and catabolism by
the liver instead of the kidney. These results suggested
that most pre-b HDLs circulating in plasma might not
be nascent particles that are undergoing maturation in
plasma but rather are terminal particles ready to be catab-
olized and incapable of mediating RCT. This concept
was further supported by the absence of radiolabeled
pre-b HDL in plasma after injection of small or large
plasma HDL tracers into nonhuman primates or hA-I Tg
mice (17, 20).
The initial and obligatory step in HDL particle assembly
is the addition of lipid to apoA-I by ABCA1, a member of
the ATP binding cassette transporter family (21). The
critical nature of this step for nascent HDL biogenesis
and for maintaining plasma HDL cholesterol levels is
demonstrated in Tangier disease subjects and ABCA1
knockout mice, both characterized by a near absence of
plasma HDL (22, 23). In a recent study, we showed that
incubation of apoA-I with human embryonic kidney
293 cells expressing ABCA1 (HEK293-ABCA1) is necessary
and sufficient to produce at least four discrete-sized pre-b
HDLs that can be isolated to apparent homogeneity (14).
These pre-b HDL particles bound poorly with ABCA1
when added back to ABCA1-expressing cells, suggesting
that other non-ABCA1-mediated pathways must function
to add more lipids and complete the maturation process.
The lack of other HDL-modifying proteins [i.e., ATP
binding cassette transporter G1 (ABCG1), phospholipid
transfer protein (PLTP), LCAT, apoM, or scavenger re-
ceptor class B type I (SR-BI)] in the HEK293 cells or con-
ditioned medium of these cells suggested that the pre-b
HDLs were nascent, rudimentary HDLs poised for mat-
uration in vivo.
The purpose of the present study was to determine the
in vivo plasma decay, interconversion, and tissue sites of
catabolism for the ABCA1-generated nascent pre-b HDLs.
Our results suggest a novel finding that the initial inter-
action of apoA-I with ABCA1 in vitro determines, in part,
the plasma remodeling and tissue site of catabolism of
these pre-b HDL particles in vivo.
METHODS
Animals
hA-I Tg mice (line 427) (24) were obtained from Charles River
Laboratories (Wilmington, MA). The mice were housed in the
Wake Forest University Health Sciences transgenic facility and
maintained on a chow diet. All protocols and procedures were
approved by the Animal Care and Use Committee of Wake Forest
University Health Sciences.
Isolation and iodination of apoA-I
Human HDLs were isolated by sequential ultracentrifugation
of human plasma, and apoA-I was isolated from HDL by GndHCl
denaturation (25, 26). The purity of the apoA-I and phosphorus
content of lipid extract from 1 mg of purified apoA-I were con-
firmed by SDS-PAGE and the method of Fiske and Subbarow
(27), respectively. ApoA-I preparations contained less than one
molecule of PL per molecule of apoA-I.
ApoA-I was coupled to 125I-radiolabeled tyramine cellobiose
(TC) (a generous gift from Dr. Steve Adelman, Wyeth-Ayerst)
as previously described (17, 28–30). Briefly, 0.01 mmol TC/mg
apoA-I protein was incubated for 10 min with 5 mCi of 125I
(carrier-free) in a microreaction vessel coated with 20 mg Iodogen
(1,3,4,6-tetrachloro-3a,6a-dephenylglycouril; Pierce Chemical
Co.). The reaction was stopped by transferring the 125I-radio-
labeled TC to a second (iodogen-free) reaction vessel contain-
ing 10 ml of 0.1 M NaHSO3 and 5 ml of 0.1 M NaI. ApoA-I was
coupled to the [125I]TC with cyanuric chloride (1:1 protein to
TC molar ratio) by incubation at room temperature for 30 min.
The [125I]TC-apoA-I was then passed over a desalting column
(Bio-Rad) to remove free iodine and dialyzed overnight in
0.15 M NaCl, 0.01% EDTA, pH 7.4. After removal from dialysis,
the tracers were assayed for protein concentration using absor-
bance at 280 nm (y 5 1.13 ml/mg), and an aliquot was taken
for radioactivity quantification.
Cell culture and ABCA1 expression
Human embryonic kidney (HEK)-293 ABCA1 (HEK293-
ABCA1) (31) cells (gift from Dr. Michael Hayden, University of
British Columbia) were maintained in DMEM supplemented
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/
ml streptomycin, and 50 mg/ml hygromycin B (Invitrogen).
HEK293-FlpIn cells were used as negative controls and cul-
tured in DMEM complete media in the presence of 50 mg/ml
Zeocin™. Cells from a rat hepatoma cell line (McA-RH7777) were
maintained in DMEM media supplemented with 10% FBS, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Mouse peritoneal macrophages (MPMs) were isolated from
the peritoneal cavity of C57BL/6 mice 4 days after intraperito-
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neal injection of 1 ml of 10% thioglycolate. The cells obtained
were washed with Media A (MEM 1 10 mM HEPES) (Cellgro;
Mediatech, Inc.), spun at 100 g for 20 min, and plated into 6-well
plates at a density of 1 3 106 cells/well in MEM supplemented
with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin,
1% MEM vitamin solution 1003 (Mediatech, Inc.), and 2 mM
L-glutamine. Cells were washed 2 h later and incubated overnight
before use in experiments.
ABCA1 expression among the different cell types (HEK293,
HEK293-ABCA1, McA-RH7777, MPM) was determined using
Western blot analysis. Total cell protein was harvested using RIPA
lysis buffer (50 mM Tris, 150 mM NaCl, 1% nonidet P-40, 10%
sodium cholate, 1 mM EDTA) containing protease inhibitors
(1 mM PMSF, 1 mg/ml pepstain, 1 mg/ml leupeptin, 1 mg/ml
aprotinin). Cellular proteins (25 mg) were separated on 4–16%
SDS-PAGE gels, transferred to nitrocellulose membranes (Schleicher
and Schuell BioScience), and incubated for 2 h at room tem-
perature with rabbit anti-human/mouse ABCA1 (1:1,000 dilu-
tion) (32) or anti-GAPDH monoclonal antibody (1:2,000; Santa
Cruz 32233), which cross-reacts with human, rat, and mouse
GAPDH. The blots were then incubated with HRP-linked anti-
rabbit IgG or anti-mouse IgG (Amersham) (1:5,000 dilution) at
room temperature for 1 h. Immunoblots were visualized with a
chemiluminescent reagent (Pierce), and the chemiluminescence
was captured with an LAS-3000 imaging system (Fujifilm Life
Science) and quantified using Multi Gauge™ software.
Formation of pre-b HDL
Control (HEK293-FlpIn) and HEK293-ABCA1 cells were plated
in 53 150 mm dishes, and McA-RH7777 cells were plated in 6-well
plates and grown until they reached 95% confluence. MPMs were
cultured for 2 days after isolation before experiments were ini-
tiated. All cells (HEK293, McA-RH7777, and MPMs) were washed
three times with serum-free medium and then incubated with
10 mg/ml of [125I]TC-apoA-I (specific activity 5 5 3 104 cpm/mg)
in serum-free medium for 24 h. The conditioned medium from
control, ABCA1, McA-RH7777 cells, and MPMs was harvested and
aliquots analyzed on 4–30% nondenaturing gradient gel electro-
phoresis (NDGGE). The remainder of the conditioned media was
concentrated using Amicon Ultra-10 concentrators and fraction-
ated on three Superdex 200 HR fast-protein liquid chromatogra-
phy (FPLC) columns (Amersham-Biosciences) connected in series
and equilibrated with 0.15 M NaCl, 0.01% EDTA, pH 7.4
(column buffer). The particles were eluted at a flow rate of
0.3 ml/min. Individual fractions were analyzed for 125I radioactiv-
ity and the 125I elution profile was plotted. An aliquot of each frac-
tion of HEK293-ABCA1 cell conditioned media was analyzed by
NDGGE to determine which fractions contained homogeneous-
sized nascent HDL particles, after which the homogeneous-sized
fractions were pooled for subsequent analyses.
In vivo turnover study
In vivo turnover studies were performed with [125I]TC-pre-b
HDL particles as previously described (17) with modifications.
Briefly, 1.5–3 3 105 cpm of the radiolabeled tracer was injected
into the jugular vein of anesthetized recipient hA-I Tg mice. Blood
samples were obtained by retro-orbital bleeding at 5 min, 30 min,
and 1, 2, 3, 5, and 24 h after dose injection to determine the
plasma decay of radiolabeled doses. Radioactivity in a 15 ml
sample of plasma was quantified using a g counter. Aliquots of
plasma from the various time points were fractionated on
NDGGE for 1,100 V-h at 10°C to determine the fractional distri-
bution of apoA-I radioactivity. After electrophoresis, gels were
exposed in a phosphorimager cassette and the images were
developed and quantified using a Typhoon 8600 (Molecular
Dynamics, Sunnyvale, CA) and ImageQuant software (version
5.2). Twenty-four hours after tracer injection, animals were eu-
thanized, tissues were harvested and digested with 1 N NaOH
overnight at 60°C, and 125I radioactivity was quantified. The re-
maining carcasses were digested with 10 g KOH in 150 ml of etha-
nol for 2–3 days; the digested carcasses were boiled in a water
bath until the volume of ethanol reached about 30 ml. All re-
maining ethanol was counted for 125I radioactivity.
Plasma volume was estimated as 3.5% of body weight, and
the total amount of radiolabel in plasma at each time point
was determined by multiplying the 125I cpm/ml by plasma
volume. For the data presented in this study, percentage of in-
jected dose remaining in plasma at each time point was deter-
mined by dividing the amount of total radioactivity in plasma
by the dose injected 3 100%. Percentage of injected dose
trapped in the tissue was calculated by dividing the 125I radioac-
tivity in a particular tissue by the dose injected 3 100%. Frac-
tional catabolic rate (FCR) values for HDL tracer decay from
whole plasma and uptake by tissues were performed using Sim-
ulation, Analysis, and Modeling (SAAM) software, as described
previously (17).
In vitro incubation study
To investigate the role of LCAT and PLTP in remodeling pre-
b HDL particles, we performed an in vitro incubation study
using C57BL/6 mouse plasma that had been immunodepleted
of LCAT or PLTP2/2 mouse plasma.
LCAT-immunodepleted plasma was prepared as follows. Pre-
immune serum and rabbit anti-mouse LCAT antisera were incu-
bated at 56°C for 20 min to inactivate LCAT. After inactivation,
either preimmune serum or rabbit anti-mouse LCAT antiserum
(0.6 of plasma volume) was added to C57Bl/6 mouse plasma and
incubated overnight at 4°C with rotation.
LCAT bound to IgG was pelleted by adding Protein A beads
to the incubation mixture, followed by a 2 h incubation at 4°C
and low-speed centrifugation. The supernatant was recovered
and had 1% of the LCAT activity (33) measured in preimmune
serum-treated plasma.
Twenty microliters of LCAT immunodepleted, preimmune-
treated plasma, or plasma from wild-type (PLTP1/1) or PLTP2/2
mice was incubated with [125I]TC radiolabeled pre-b1, -2, -3 and -4
HDL particles (20,000 cpm) at 4°C for 1 h or 37°C for 5 or 60 min.
Subsequently, incubated plasma samples were resolved on 4–30%
NDGGE and gels were analyzed by phosphorimager analysis.
In vitro reactivity of pre-b HDL with LCAT
To determine the reactivity of individual pre-b HDL particles
with LCAT, pre-b1, -2, -3 and -4 HDLs were prepared using the
same protocol as described above, except that cells were radio-
labeled with [3H]cholesterol for 24 h before incubation with
apoA-I. Aliquots of pre-b1, -2, -3, and -4 HDL (104 dpm of [3H]
cholesterol) were then incubated with 50 ng of purified human
recombinant LCAT in 0.5 ml of buffer (10 mM Tris, pH 7.4,
140 mM NaCl, 0.01% EDTA, 0.07% NaN3, 0.6% BSA, 2 mM b-
mercaptoethanol) at 37°C for 1 h as described previously (33,
34). After incubation, the samples were lipid-extracted and free
cholesterol and CE radiolabels were separated and quantified.
Statistical analysis
Differences among the genotypes of mice were analyzed using
one-way ANOVA, followed by Tukeyʼs multiple comparison test to
identify individual differences. All statistical analyses were per-
formed using GraphPad Prism 4 (GraphPad Software, Inc., San
Diego, CA).
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RESULTS
Nascent pre-b HDL formation by ABCA1 cells
We previously reported that several heterogeneous-sized
nascent pre-b HDL particles were generated by incubation
of apoA-I with HEK293 cells stably transfected with ABCA1
(14). To evaluate whether the formation of these hetero-
geneous-sized nascent pre-b HDL particles was uniquely
related to the level of ABCA1 overexpression in HEK293
cells, we compared ABCA1 expression and HDL particle
formation using HEK293 cells stably transfected with hu-
man ABCA1, McA-RH7777 cells, and MPMs. Western blot
analysis demonstrated that HEK293-ABCA1 cells expressed
approximately 1.5- and 2.5-fold more ABCA1 protein com-
pared with McA-RH7777 cells and elicited MPMs, respec-
tively, whereas HEK293 cells had only background levels of
ABCA1 expression (Fig. 1A). Despite the relatively modest
increased level of ABCA1 protein expression in ABCA1-
expressing HEK293 cells, the size distribution of nascent
HDL particles was similar among the three cell types, as
demonstrated by NDGGE (Fig. 1B) and high-resolution
FPLC (Fig. 1C). However, the relative distribution of par-
ticles did change among cell types, with McA-RH 7777
cell medium containing a relative enrichment of larger
pre-b HDL (i.e., pre-b3 and -4) (Fig. 1B). These results
suggested that nascent HDLs assembled by human ABCA1
expressed in HEK293 cells were similar to those assembled
by hepatoma cells and macrophages.
Fig. 1. Analysis of ABCA1 expression and nascent pre-b HDL size distribution from different cell types. A:
ABCA1 protein expression by Western blot. Twenty-five micrograms of cell lysate protein isolated from
HEK293-FlpIn cells (non-transfected control), HEK293 cells stably transfected with ABCA1, rat McArdle-
RH7777 hepatoma cells, and elicited mouse peritoneal macrophages (MPMs) were separated by 4–16%
SDS-PAGE. Proteins were then transferred to a nitrocellulose membrane, blotted with rabbit anti-mouse
ABCA1 antisera or anti-GAPDH monoclonal antibody, and developed by chemiluminescence using an
LAS-3000 imaging system (FujiFilm). Images were quantified using Multi Gauge software and normalized
to GAPDH expression. For comparison among cell types, the relative expression of ABCA1 was normalized
to McArdle cells. B: Nascent pre-b HDL size distribution determined by 4–30% nondenaturing gradient
gel electrophoresis (NDGGE). Nontransfected (HEK293) and stably transfected (HEK293-ABCA1) cells,
McArdle-RH7777 cells, and elicited MPMs were incubated with 10 mg/ml of [125I]tyramine cellobiose
(TC)-apolipoprotein A-I (apoA-I) for 24 h. Aliquots of conditioned media were subfractionated by NDGGE,
and nascent HDLs were visualized by phosphorimager analysis. Numbers shown on left side are nm diam-
eter. C: Nascent HDL fractionation by high-resolution fast-protein liquid chromatography (FPLC). [125I]TC-
apoA-I (10 mg/ml) was incubated for 24 h with the indicated cells, after which the conditioned medium
was fractionated by FPLC. Radiolabel in fractions from the FPLC separation was quantified by g counting
and represented a percentage of total count recovered from the column. Vertical dashed lines denote frac-
tions corresponding to pre-b1 to -5 HDL tracers. D: NDGGE and phosphorimager analysis of an aliquot
of FPLC-fractionated pre-b1 to -5 HDL tracers generated by incubation of [125I]TC-apoA-I with HEK293-
ABCA1 cells for 24 h. Numbers above each lane denote pre-b HDL fraction. HMW, high-molecular-weight
standard. Numbers shown on left side are nm diameter.
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Preparation of nascent pre-b HDL tracer
Nascent pre-b HDL tracers for in vivo turnover studies
were generated by incubating [125I]tyramine cellobiose-
apoA-I ([125I]TC-apoA-I) with HEK293-ABCA1 cells for
24 h. ApoA-I was coupled with [125I]TC, a tissue-residualizing
compound, allowing us to determine tissue sites of catabo-
lism of the injected doses. Following incubation of [125I]
TC-apoA-I with HEK293-ABCA-expressing cells, the condi-
tioned medium was fractionated by FPLC, and pre-b HDL
elution from the column was monitored by g counting. As
shown in Fig. 1C (black circles), five distinct peaks were
eluted from post-fractionation of ABCA1 cell-conditioned
medium after FPLC. Fractions for each peak were pooled,
as indicated by the vertical dashed lines in Fig. 1C, and
designated as pre-b1, -2, -3, -4, and -5, from the smallest
to the largest particle size. Aliquots of each pool were
subjected to NDGGE, and gels were developed using a
phosphorimager (Fig. 1D). These results show that five
discrete-sized pre-b HDLs of apparent homogeneity were
isolated by the FPLC procedure. Using two-dimensional gel
electrophoresis (14), we observed that all nascent HDL
migrated in the pre-b position (data not shown). Suffi-
cient amounts of pre-b1 and -4 were available for in vivo
turnover studies.
Plasma turnover and tissue uptake of nascent pre-b HDLs
in hA-I Tg mice
Isolated homogeneous-sized pre-b HDLs (pre-b1, -2, -3,
and -4) were injected into hA-I Tg-recipient mice to monitor
the in vivo metabolic fate of the particles. For all tracers,
the injected apoA-I tracer mass was about 5 mg per animal
(33 105 cpm per mouse/63 104 cpm/mg5 5 mg/mouse)
and represented approximately 0.17% of the total plasma
apoA-I mass in hA-I Tg mice (plasma apoA-I pool size 5
?3,000 mg) (35). Plasma was drawn from recipient mice
at the indicated times to determine the kinetics of turn-
over of the tracers in the circulation. Plasma die-away
curves for each tracer are shown in Fig. 2A. The plasma
Fig. 2. Whole-plasma decay, plasma fractional catabolic rate (FCR) and tissue uptake of pre-b HDL tracers in human apolipoprotein A-I
transgenic (hA-I Tg) mice. [125I]TC-pre-b1, -2, -3, and -4 HDLs were injected into hA-I Tg mice, and plasma samples were drawn over 24 h,
after which animals were euthanized and tissues were harvested and digested to quantify radiolabel uptake. Data represent mean 6 SD (n 5
4 for all tracers). A: Whole-plasma decay of pre-b HDL tracers in hA-I Tg mice. Radioactivity of plasma samples at each time point was
quantified and percent of injected radioactivity remaining in the plasma after dose injection was plotted versus time. B: Plasma FCR of
pre-b HDL tracers in hA-I Tg mice. FCR is expressed as pools/day. Values were calculated using SAAM software and a two-pool model with
rate constants from the plasma pool to the liver and kidney, as described in the Methods section. C: Percentage of injected dose recovered
in liver and kidney. Liver and kidney were harvested at the end of the study and digested overnight with 1 N NaOH at 60°C. Digested tissues
were quantified for 125I radioactivity and expressed as percentage of initial dose. Statistical analysis was performed using one-way ANOVA
with Tukeyʼs multiple comparison test to ascertain individual differences within a tissue. Bars with different letters are significantly different
from one another at P , 0.05.
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die-away of all tracers was similar except that of pre-b1
HDL tracer, which was cleared from the plasma signifi-
cantly faster than the others. Analysis of plasma kinetic data
demonstrated a 7-fold greater FCR for pre-b1 (13.58 6
5.16 pools/day) compared with pre-b2 (2.13 6 0.53 pools/
day), pre-b3 (1.68 6 0.66 pools/day), and pre-b4 (2.07 6
1.04 pools/day), which were not significantly different
from one another (Fig. 2B).
To identify the catabolic sites of the nascent pre-b HDL
tracers in hA-ITg mice, tissues were removed from recipient
mice 24 h after tracer injection and quantified for radio-
label uptake as percentage of injected tracer. The liver
and kidney were the only organs that were quantitatively
significant in the uptake and catabolism of the radiola-
beled tracers and together represented .90% of radiolabel
uptake (see supplementary Fig. I). Figure 2C summarizes
the percentage of tissue uptake of injected tracers in the
liver and kidney. In the liver, pre-b1 HDL tracer uptake
was significantly less than that of pre-b2 and -3, and uptake
of pre-b4 was significantly higher than the other tracers.
Thus, there was a trend of increased liver tracer uptake
with increasing initial nascent pre-b HDL size. The oppo-
site trend, however, was observed for kidney uptake. Pre-b
1 tracer uptake was significantly higher than the other
tracers and pre-b3 and -4 uptake was significantly lower
than pre-b2. The data suggest that kidney uptake of pre-b
HDL tracer was inversely related to initial pre-b HDL size.
Plasma turnover and tissue uptake of apoA-I and
lipid-poor nascent pre-b1 HDLs in hA-I Tg mice
Previously, we reported that pre-b1 HDL particles as-
sembled by ABCA1 are similar in size, but distinct from
lipid-free apoA-I in chemical composition, density, binding
to ABCA1, and lipid efflux potential (14). To evaluate
whether apoA-I and lipid-poor nascent pre-b1 HDLs have
different in vivo metabolic fates, we compared the plasma
turnover and tissue uptake of apoA-I and pre-b1 HDL
tracers in hA-I Tg mice. Pre-b1 HDL had a faster plasma
turnover rate compared with apoA-I tracer, as shown in
Fig. 3A. Analysis of plasma FCR using SAAM software
showed that plasma FCR of pre-b1 HDL tracer (13.6 6
5.2 pools/day) was 6-fold higher than that for apoA-I
(2.2 6 0.2 pools/day) (Fig. 3B), which is similar to the
turnover rate of pre-b2, -3, and -4 HDL tracers (Fig. 2B).
The apoA-I tracer was preferentially metabolized in the
liver rather than the kidney (Fig. 3C), but the pre-b1
HDL tracer was preferentially metabolized in the kidney.
These results suggest that apoA-I and lipid-poor pre-b1
HDL tracers are metabolized differently in vivo.
In vivo remodeling of nascent pre-b HDL in hA-I Tg mice
An aliquot of plasma from each time point of the in vivo
turnover study was fractionated by NDGGE, followed by
phosphorimager analysis, to investigate the remodeling
of each pre-b HDL subfraction during the 24 h turn-
over. Figure 4 shows gel images from a representative
mouse injected with [125I]TC-apoA-I and pre-b1, -2, -3 and
-4 HDL tracers. Unlike the plasma die-away data (Fig. 2A),
HDL subfraction distribution of the remodeled pre-b HDL
tracers in plasma was more complicated. At the earliest
time point examined (5 min), nearly all of the radiolabeled
apoA-I was distributed in the medium HDL size range (8–
10 nm in diameter), and this distribution varied little over
the 24 h time course of the study (Fig. 4, upper left panel).
In contrast, at the 5 min time point, some of the pre-b1
HDL tracer was distributed in the medium HDL size range,
whereas some remained in the pre-b1 size range (,7.1 nm)
Fig. 3. Whole-plasma decay, plasma FCR, and tissue uptake of
apoA-I and pre-b1 HDL tracers in hA-I Tg mice. [125I]TC-apoA-I
and pre-b1 HDL tracers were injected into hA-I Tg mice (see Fig. 2
legend). A: Whole-plasma decay of apoA-I and pre-b1 HDL tracers
in hA-I Tg mice. B: Plasma FCR of apoA-I and pre-b HDL tracers
in hA-I Tg mice. C: Percentage of injected dose recovered in liver
and kidney of apoA-I and pre-b1 HDL tracers in hA-I Tg mice.
Statistical analysis was performed using one-way ANOVA with
Tukeyʼs multiple comparison test to ascertain individual differ-
ences. Bars with different letters are significantly different from
one another at P , 0.05. Error bars indicate SEM.
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(Fig. 4, upper middle panel). This pattern of in vivo remo-
deling resembled that in a previous study using plasma-
isolated pre-b HDL (17). The pre-b2 HDL tracer remodeled
into at least four distinct HDL size ranges between 7 and
13 nm in diameter, three of which were larger than the in-
jected tracer (Fig. 4, upper right panel). In contrast, the pre-
b3 HDL tracer was distributed into three distinct size ranges
between 7 and 10.4 nm in diameter, one of which was similar
in size to the injected pre-b3 HDL (Fig. 4, lower left panel).
Pre-b4 HDL tracer was distributed into three smaller HDL
particles, ,10 nm in diameter, all of which were smaller
than the original pre-b4 HDL tracer (Fig. 4, lower right
panel). Thus, even though the whole-plasma decay for
pre-b2, -3, and -4 HDL tracers was similar, the remodeling
of these tracers in plasma was distinctly different, with
apoA-I and pre-b1 and -2 remodeled into larger particles
and pre-b3 and -4 remodeled into smaller particles.
Using phosphorimager analysis of NDGGE data similar
to those in Fig. 4, we quantified the amount of radiolabel
associated with particles,7.1 nm in diameter and particles
in the medium HDL size range (8–10 nm) for each time
point of the apoA-I and pre-b1 HDL tracer turnover stud-
ies (using ImageQuant Software), followed by analysis
with the SAAM II program. Five minutes after injection,
62.6% of the pre-b1 tracer remained as pre-b1 (,7.1 nm),
and was removed from the circulation at an extraordinarily
rapid rate (FCR 92.92 6 5.85 pools/day); the remaining
22.8% of pre-b1 tracer was remodeled to medium-sized
HDLs, which were removed from circulation much more
slowly (FCR 7.76 6 4.75 pools/day). Additional analyses
suggested that as much as 97.7% of radioactivity found in
kidney of animals injected with pre-b1 HDL tracers could
be accounted for by the pre-b1 tracer, which was rapidly
removed from circulation and not converted to larger
particles during the first 5 min after injection (data not
shown). This suggests that pre-b1 HDL particles not imme-
diately converted to or associated with medium-sized HDL
within 5 min after injection are removed rapidly from cir-
culation by the kidney. Kinetic analysis also suggested that
radioactivity recovered in the liver of mice injected with
pre-b1 HDL tracer was derived almost exclusively from
pre-b1 tracer that was remodeled into medium-sized HDL.
Similar kinetic results were observed for plasma-isolated
pre-b HDL in our previous study (17).
In vitro remodeling of nascent pre-b HDL tracers
To determine whether HDL-remodeling factors such as
LCAT (36) and PLTP (37, 38) promote nascent pre-bHDL
remodeling in vivo, we performed in vitro incubations of
mouse plasma with nascent pre-b HDL tracers. To investi-
gate the role of LCAT, we performed an in vitro incubation
of nascent pre-b HDL tracers with either control or LCAT-
immunodepleted plasma. LCAT was immunodepleted
from plasma using anti-mouse LCAT antibody, which re-
duced LCAT activity by 99% compared with preimmune
serum-incubated plasma (control). The role of PLTP in
nascent pre-b HDL remodeling was also investigated by
incubation of nascent pre-b HDL tracers in wild-type ver-
sus PLTP2/2 mouse plasma. Because most of the in vivo
remodeling occurred within the first hour after tracer in-
jection, each tracer was incubated with plasma for 5 or
60 min at 37°C, or 60 min at 4°C as a control. At the
Fig. 4. Size distribution of pre-b HDL tracers after intravenous injection into hA-ITg-recipient mice. Plasma
samples were harvested at the indicated times after [125I]TC-apoA-I and pre-b1, -2, -3, and -4 HDL tracer
injection. Plasma samples (15 ml aliquot) were fractionated on 4–30% NDGGE, and radiolabel distribution
was visualized using a phosphorimager. A phosphorimager result of one representative recipient mouse
for each tracer is shown. HMW protein standard (lane 1) and dose (lane 2) are shown for reference. Lanes
3–9 contain plasma samples taken at 5 min, 30 min, and 1, 2, 3, 5, and 24 h, respectively.
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end of incubation, plasma samples were fractionated by
NDGGE and phosphorimager analysis was performed to
follow the tracer remodeling. A representative experiment
is shown in Fig. 5. No apparent remodeling of any pre-b
HDL tracer occurred with 60 min incubation at 4°C (lanes
2 and 3 for each gel in top and bottom panel). However,
incubation of pre-b HDLs in control plasma for 5 min
(lane 4) or 60 min (lane 6) at 37°C resulted in remodeling
to medium-sized HDL (8–10 nm) for pre-b1 and -2 tracer
and remodeling to small HDL (7–8 nm) for pre-b3 and -4
tracers. In the absence of active LCAT (Fig. 5, top panel),
tracer remodeling was still observed with 5 min (lanes 4
vs. 5) and 60 min (lane 6 vs. 7) incubations at 37°C, sug-
gesting that LCAT is not an absolute requirement for re-
modeling of nascent pre-b HDL. A different result was
observed in the absence of PLTP. Remodeling of all
nascent pre-b HDL tracers at 37°C was significantly de-
creased in PLTP2/2 plasma (Fig. 5, lower panel, lanes 5
and 7) compared with wild-type control plasma (Fig. 5,
lower panel, lanes 4 and 6), suggesting that PLTP is neces-
sary for remodeling of nascent pre-b HDL.
In vitro reactivity of pre-b HDL with LCAT
To determine LCAT reactivity with each pre-b HDL par-
ticle, we performed in vitro incubations using purified
human recombinant LCAT (Fig. 6). All pre-b HDL parti-
cles were reactive with LCAT, and particle reactivity in-
creased with increasing pre-b HDL size.
DISCUSSION
Pre-b HDLs represent 5–10% of the plasma HDL pool
(12) and are the nascent precursor particles to mature,
spherical HDLs. The formation of pre-b HDL particles
by ABCA1 is the first committed step in HDL formation
and results in particles that can participate in RCT by
removing excess cholesterol from tissues. Despite the im-
portance of pre-b HDLs as intermediates in HDL particle
formation and RCT, very little is known about their me-
tabolism in vivo. We showed previously that addition of
apoA-I to cells expressing ABCA1 results in the formation
of up to five distinct pre-b HDL subfractions with increas-
ing size and lipid-to-protein ratios (14). The goal of this
study was to determine the in vivo metabolic fate of these
pre-b HDLs. Surprisingly, the removal rate of pre-b HDLs
from plasma was very similar for pre-b2, -3, and -4 HDL
tracers and comparable with apoA-I tracer, but was much
faster for pre-b1 HDL. Although the plasma die-away
curves were similar among the larger pre-b HDLs (i.e., -2,
-3, and -4), intravascular remodeling of the pre-b HDL
tracer after injection was complex, with pre-b1 and -2 re-
modeled predominantly into larger particles and pre-b3
Fig. 5. In vitro remodeling of pre-b HDL tracers in the presence or absence of LCAT or PLTP. [125I]TC-
radiolabeled pre-b1 to -4 HDLs were incubated with plasma with or without LCAT (top panel) or PLTP
(lower panel). C57Bl/6 mouse plasma was incubated with anti-mouse LCAT antiserum to immunodeplete
LCAT or preimmune serum (control) (see Methods section). LCAT immunodepletion was .99% compared
with preimmune incubated plasma. Plasma from wild-type (WT) or PLTP2/2 plasma was used to investigate
pre-b HDL remodeling in the presence or absence of PLTP. Incubations were performed for 1 h at 4°C or
for 5 min and 1 h at 37°C. Aliquots of the incubation mixtures were subjected to 4–30% NDGGE and devel-
oped with a phosphorimager. Top panel, incubations 6 LCAT; bottom panel, incubations 6 PLTP. 1: HMW
marker; hydrodynamic size of standard proteins is shown on the left; 2: WT, 4°C, 1 h; 3: LCAT-depleted
(2LCAT) or PLTP2/2, 4°C, 1 h; 4: WT, 37°C, 5 min; 5: 2LCAT or PLTP2/2, 37°C, 5 min; 6: WT, 37°C,
1 h; 7: 2LCAT or PLTP2/2, 37°C, 1 h.
In vivo metabolism of nascent HDL assembled by ABCA1 2397
and -4 remodeled into smaller particles. The nature of
this rapid remodeling is unknown; however, it appears
to be dependent on PLTP activity, but not LCAT activity,
even though we show that the pre-b HDLs are reactive
with LCAT in vitro (Fig. 6). Finally, despite the differences
in remodeling, the tissue uptake of pre-bHDLs was related
to the initial particle size assembled by ABCA1, such that
as initial pre-b HDL size increased, more particles were
taken up by the liver and fewer by the kidney. Given these
results, larger pre-b HDLs would seem likely to accept
more cholesterol from peripheral tissue and to be prefer-
entially taken up by the liver. Even though selective choles-
terol uptake (i.e., uptake of core CE without whole-particle
uptake) makes a greater contribution to RCT than whole-
particle HDL uptake by the liver (39), increased uptake
and degradation of HDL particles would still enhance
RCT. Thus, our studies suggest that the initial interaction
of apoA-I with ABCA1 is necessary to assemble pre-b HDLs
and also appears to predetermine, to some extent, the ulti-
mate in vivo metabolic fate of pre-b HDLs.
Studies in Tangier subjects and ABCA1 gene-targeted
mice have shown that ABCA1 is absolutely required for
HDL formation (22, 23). It is now clear that ABCA1 func-
tions to assemble apoA-I with cellular lipid to form nascent
pre-b HDLs (40, 41). We and others have shown that incu-
bation of apoA-I with cells expressing ABCA1 is necessary
and sufficient to generate multiple-sized pre-b HDL sub-
fractions that appear to be formed simultaneously in cell
culture media (14, 42–45). We observed that these pre-b
HDLs, once formed and isolated, are poor substrates
for subsequent binding to ABCA1 and lipid efflux (14,
46), suggesting that the initial interaction of ABCA1 with
apoA-I or the addition of lipid to apoA-I via ABCA1 results
in a conformational constraint in apoA-I that diminishes its
ability for subsequent interaction with ABCA1. A corollary
to this observation is that addition of lipid to these pre-b
HDLs requires other proteins, such as PLTP, ABCG1,
and/or SR-BI, to undergo further maturation; this idea
has been supported by direct experimentation (47–49).
Our current study extends these findings to in vivo metab-
olism and suggests that the initial interaction of apoA-I
with ABCA1 results in a type of “metabolic imprinting”
that predetermines the tissue site of uptake of the pre-b
HDLs. For instance, we found similar plasma die-away
curves for pre-b2 and -4 HDLs (Fig. 2A, B). However, in
plasma, pre-b2 HDL is remodeled into larger particles,
on average, whereas pre-b4 HDL is remodeled into smaller
ones. Despite this intravascular remodeling, which results
in some overlapping particle size ranges for pre-b2 and
pre-b4 HDL tracers (Fig. 4), significantly more of the
pre-b4 tracer is removed from circulation by the liver
and less by the kidney, compared with pre-b2 (Fig. 2). In
other words, the larger the pre-b HDL produced by the
interaction of apoA-I with ABCA1, the more likely is the
nascent pre-b HDL to be catabolized by the liver, in what
probably is one of the final steps in HDL particle RCT.
Thus, our study suggests a role for ABCA1 in determining
the metabolic fate of pre-b HDL in vivo, which may influ-
ence the degree to which pre-b HDLs participate in whole-
particle RCT.
Pre-b1 HDLs, sometimes referred to as lipid-poor apoA-
I, are distinct from other pre-b HDLs and from lipid-free
apoA-I. Our previous studies have documented that pre-b
1 HDLs contain only a few molecules of PL and one
molecule of apoA-I (14, 17). We observed that despite
the very low lipid content, isolated pre-b1 HDLs bind
poorly to ABCA1 and are poor acceptors for lipid efflux,
suggesting that apoA-I conformation has been constrained
by its initial interaction with ABCA1 (14). Indeed, thermal
denaturation of pre-b1 by heating to 60°C for 30 min
resulted in partial recovery of binding, supporting the con-
cept that the constrained conformation of apoA-I induced
by interaction with ABCA1 is relieved by thermal unfold-
ing, which allows recovery of binding to ABCA1 (14).
Recently, Duong et al. (50) reported the formation of a
similar lipid-poor pre-b1 HDL population by skin fibro-
blasts in which ABCA1 activity was stimulated by 9-cis-
retinoic acid and 22-hydroxycholesterol. However, in their
study, pre-b1 HDL particles effluxed cholesterol as effi-
ciently as lipid-free apoA-I. The apparent discrepancy in
results may be related to small differences in PL content
due to differences in incubation time, or other experimen-
tal variables (i.e., cell type, level of ABCA1 expression).
The combined results suggest a critical amount of PL
may be necessary to “constrain” apoA-I on pre-b1 HDL
into a conformation that no longer allows interaction with
ABCA1 and lipid efflux.
The in vivo metabolism of pre-b1 HDLs is also distinct
from that of other pre-b HDL particles and lipid-free
apoA-I. Pre-b1 HDLs are rapidly removed from plasma
by the kidney and are not likely to undergo extensive
remodeling in plasma. The remodeling of some of the
pre-b1 tracer to medium-sized HDL may stem from the
presence of lipid-free apoA-I in the preparation, which
Fig. 6. In vitro reactivity of pre-b HDL with human LCAT. Indi-
vidual pre-b HDLs were assembled and isolated (see Fig. 1 legend).
An equal amount of pre-b HDL cholesterol (104 dpm) was incu-
bated with 50 ng of purified human recombinant LCAT at 37°C
for 1 h (see Methods). The incubation mixtures were then lipid
extracted and the percentage of radiolabeled free cholesterol con-
verted to cholesteryl ester was determined. The percentage choles-
terol esterification in the absence of added LCAT enzyme (i.e.,
blank) was measured and subtracted from that measured in the
presence of LCAT for each pre-b HDL particle. Results present
duplicate incubations, with the horizontal line denoting the aver-
age value of the duplicates.
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cannot be distinguished or separated from pre-b1 HDL by
existing experimental methodologies. In fact, the most
sensitive measurement of lipid-free apoA-I content in the
pre-b1 HDL preparation appears to be the rapid remodel-
ing of radiolabel to medium-sized HDLs, because we have
shown here (Fig. 4) and previously (17) that radiolabeled
lipid-free apoA-I is transferred quantitatively to medium-
sized HDLs within 5 min after injection into recipient
mice. Unlike lipid-free apoA-I, which can readily and
rapidly transfer to medium-sized HDLs (17, 51), pre-b1
HDLs appear unable to do so. We speculate that a few
molecules of PL in pre-b1 HDL are enough to stabilize
the structure of apoA-I, preventing its interaction with
ABCA1 and its association or transfer to preexisting plasma
HDL particles. Taken together, our results suggest that
pre-b1 HDLs in plasma are terminal particles that are
not sufficiently lipidated by ABCA1 to prevent their pre-
mature removal from the circulation by the kidney. In-
sufficient lipidation of apoA-I may occur due to limited
availability of ABCA1 expression on the cell surface, lim-
ited availability of cellular lipid, or both. If our hypoth-
esis is correct, any perturbation that results in additional
lipidation of apoA-I to produce relatively more pre-b2, -3,
or -4 HDLs, rather than pre-b1, will result in a proportional
increase in catabolism of pre-b HDLs by the liver and may
enhance HDL whole-particle RCT.
Another novel and surprising finding of our study was
the remodeling of pre-b HDL tracers in plasma after injec-
tion. Subsequent studies showed that tracer remodeling
also occurred with in vitro incubation in plasma, dem-
onstrating that the remodeling factors were available in
plasma. Although the molecular nature of this remodeling
process is unknown, it requires active PLTP (Fig. 5), which
has been shown to remodel plasma HDL particles into
larger and smaller HDL products (37, 38). Interestingly,
we observed in our in vivo and in vitro studies that pre-b1
and -2 HDLs were remodeled into larger particles, whereas
pre-b3 and -4 HDLs were remodeled into smaller, average-
sized HDLs. The very rapid nature of the remodeling
(,5 min) suggested that it might involve pre-b HDL
fusion with, or transfer to, preexisting plasma HDL parti-
cles. However, the data do not support random exchange
of radiolabeled apoA-I, inasmuch as remodeling occurred
in discrete size ranges of HDL (Figs. 4, 5), not through-
out the entire range of particle sizes, and required PLTP
and 37°C incubation. We also observed that pre-b HDL
particles were reactive with LCAT (Fig. 6); however, LCAT
activity was not necessary for remodeling. A similar con-
clusion was reached in our previous study, in which in vitro
remodeling of plasma isolated pre-b HDLs, which were
similar in size and composition to the pre-b1 HDLs in this
study, occurred unabated in the presence of an LCAT in-
hibitor (35). These data do not contradict the essential
role for LCAT in the maturation of nascent discoidal pre-
b HDLs to spherical plasma HDLs through cholesterol
esterification (52–55). Rather, they suggest that choles-
terol esterification was not a necessary prerequisite for
rapid remodeling in our study. Other plasma factors that
have been shown to remodel HDL particles, such as CE
transfer protein and hepatic lipase, were not investigated
in the present study (13). Further studies are required to
define the molecular nature of the rapid remodeling of
ABCA1-generated pre-b HDLs in plasma.
To our knowledge, this is the first study to define the
in vivo metabolic fate of pre-b HDL particles assembled
by ABCA1, and the results fill some critical gaps in our
knowledge regarding HDLmetabolism. It is now clear from
our studies in tissue-specific ABCA1 knockout mice that
nearly all of the plasma HDL pool can be accounted for
by liver and intestinal production (32, 57). It is also inter-
esting that only these two tissues quantitatively produce
apoA-I (56). There is also mounting evidence that assembly
of most HDL particles occurs at the cell surface (45, 58–64)
or in a recycling endosomal compartment by ABCA1 (65–
70) and not in the secretory pathway of the endoplasmic
reticulum and Golgi apparatus (71). Because we have
shown that poorly lipidated apoA-I (i.e., pre-b1 HDL) is
rapidly catabolized by the kidney, whereas lipid-free
apoA-I rapidly and quantitatively transfers to plasma HDLs
(17, 51), newly synthesized apoA-I from hepatocytes or
intestinal epithelial cells has several metabolic fates. If
apoA-I escapes lipidation in the secretory pathway and
at the cell surface by ABCA1, it is likely to associate with
mature HDL particles after entering the circulation (17,
51). If lipidation in the secretory pathway or at the cell
surface by ABCA1 is sufficient to form pre-b2, -3, or -4
HDLs, these particles will undergo further lipidation by
non-ABCA1-mediated pathways and ultimately be con-
verted to mature plasma HDL particles by LCAT in plasma.
If, on the other hand, apoA-I is poorly lipidated, with
only a few molecules of PL in the secretory pathway or
by ABCA1 at the cell surface, it will not contain enough
lipid to prevent its rapid clearance from plasma by the
kidney. Thus, increasing hepatic or intestinal ABCA1 ex-
pression in the absence of increased lipid availability or
increasing hepatic or intestinal apoA-I secretion in the
absence of increased ABCA1 expression may not result in
a proportional increase in plasma HDL concentration.
The authors thank Dr. Michael Hayden from the University of
British Columbia, Vancouver, Canada for providing us with
ABCA1-expressing cells.
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